New guidelines and the continuous modification of current policies will be needed in order to establish and maintain an appropriate professional relationship between physicians and pharmaceutical companies.
Physicians need to inform parents about the limited effectiveness of growth hormone therapy in satisfying the treatment goals of children with idiopathic short stature.